Kumari et al Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):315-321 ISSN: 2250-1177 [315] CODEN (USA): JDDTAO Available online on 15.08.2019 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open Access to Pharmaceutical and Medical Research © 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited Open Access Research Article Formulation Development & Evaluation of Buffered Tablet of Proton Pump Inhibitors Drug Rabeprazole Sodium Mamta Kumari*, Dr. Nishi Prakash Jain *Sagar Institute of Research & Technology- Pharmacy, Bhopal, Madhya Pradesh 462041 ABSTRACT The aim of present study was to prepare buffered tablets of acid labile drug, Rabeprazole sodium for oral administration using buffering agents to protect a drug from gastric fluid. Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+, K+ATPase at the secretory surface of the gastric parietal cell. Rabeprazole blocks the final step of gastric acid secretion. The tablets were prepared by direct compression and wet granulation method. The formulations contain water soluble buffers such as sodium bicarbonate and trisodium phosphate as well as water insoluble buffers as magnesium oxide, magnesium hydroxide and calcium carbonate and crospovidone as superdisintegrant. Preformulation studies like angle of repose, bulk density, tapped density, Carr’s index, hausner’s ratios, DSC and drug/excipient compatibility study were conducted and evaluated for hardness, friability, weight variation, drug content, disintegration and in-vitro dissolution. In the present study, pH of F6 batch was found to be optimum and disintegration time is 42 sec. The drug release was found to show maximum drug release in case of F6 with 99.3% in 60 minutes. In case of stability studies study of the optimized batch, all the results were found to be satisfactory and within limits. There were no significant changes after the period of 1 month study. Keywords: Rabeprazole sodium, Proton-pump inhibitors, Buffered tablet, Superdisintegrants, Buffering agents Article Info: Received 08 June 2019; Review Completed 22 July 2019; Accepted 26 July 2019; Available online 15 August 2019 Cite this article as: Kumari M, Jain NP, Formulation Development & Evaluation of Buffered Tablet of Proton Pump Inhibitors Drug Rabeprazole Sodium , Journal of Drug Delivery and Therapeutics. 2019; 9(4-s):315-321 http://dx.doi.org/10.22270/jddt.v9i4-s.3324 *Address for Correspondence: Miss Mamta Kumari, Sagar Institute of Research & Technology, Pharmacy, Bhopal, Madhya Pradesh 462041 INTRODUCTION Rabeprazole sodium drug is a sodium salt of 2-((4-(3- methoxypropoxy)-3-methylpyridin-2-yl) methylsulfinyl)-1H- benzo[d]imidazole belongs to a class of proton pump inhibitors. It suppress gastric acid secretion by specifically inhibiting the H + /K + - ATPase enzyme system at the secretory surface of the gastric parietal cell 1 . Peptic ulcer disease comprises a group of chronic ulcerative conditions that primarily affect the gastric mucosa and proximal duodenum. The drug like H2 blockers cimetidine, ranitidine and famotidine reduce the amount of acid produced by stomach. But Proton Pump Inhibitors (PPIs) are a group of drugs whose main action is pronounced and long-lasting reduction of gastric acid production. These drugs are metabolized in the parietal cells to active sulfonamide metabolites that inactivate the sulfhydryl group of the proton pump, thus reducing the hydrogen ion secretion 2,3 . Most of the PPIs are formulated in an enteric-coated solid dosage form (either a delayed-release capsule or tablet) or as an intravenous solution. There are some problems associated with enteric- coated preparations as dissolution of the enteric coating is pH-dependent and gastric empting time. pH profile of the gastrointestinal tract in an individual is variable at different times and is dependent on numerous physiological factors (e.g., the fed or fasted state), variable dissolution times for the enteric coat and variable pharmacokinetic profiles of individuals may affects 4-6 . The acid-labile drugs for oral administration may also be protected from gastric acidity by neutralizing the pH of the gastric fluid. So the current frontier in PPI therapy is immediate-release tablet combined with buffering agents which prevent degradation of drug by neutralizing the pH of stomach before absorption and protect the drug from low pH. Such dosage forms are known as buffered tablet and such tablet is advantageously devoid of any enteric coating or delayed or sustained-release delivery 7,8 . MATERIAL AND METHOD Material Rabeprazole sodium was obtained as gift sample from Cadila Healthcare Ltd., Ahmedabad. All chemicals were used of pharmaceutical grade obtained as gift sample from apex pharmaceutical, Chennai.